Autolus Therapeutics plc — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Autolus announced Q2 2026 AUCATZYL net product revenue of approximately $45 million with 35% gross margin year-to-date. The company secured a five-year, interest-only credit facility from Perceptive Advisors for up to $250 million ($75 million funded at closing on July 30, 2026; $25 million optionally available within 6 months; $150 million conditional on revenue milestones). FY 2026 sales guidance raised to $140–$150 million from $120–$135 million. Autolus issued a warrant for 3.5 million ADSs at $1.9314 per ADS. Interest rate: SOFR + 7.25% (3.50% SOFR floor).
Why this rating
Material financing (45.6% of market cap) plus guidance raise and strong Q2 revenue growth (70% QoQ, >100% YoY) with margin inflection. Real but execution-dependent.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.